missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Gibco™ Human IFN-alpha A (alpha 2a) Recombinant Protein
Beschreibung
Dilution Recommendation: Further dilutions should be made in medium or buffered solution containing carrier protein such as PBS with 0.1% BSA.
IFN alpha (Interferon alpha) is a Type I interferon belonging to a family of structurally related, species-specific proteins exclusive to vertebrates. The interaction of IFN-alpha with its receptor component result in the activation of a number of signaling pathways which are mainly involved in innate immune response against viral infection. In humans, the gene for IFN alpha is located on on chromosome 9. The type I interferons consist of 14 different alpha isoforms (subtypes with slightly different specificities), and single beta, omega, epsilon and kappa isoforms. Homologous molecules are found in many species, including rats and mice (and most mammals), and have been identified in birds, reptiles and fish species. IFN alpha is produced primarily by plasmacytoid dendritic cells, is a potent component of the anti-viral innate immune response and modulates adaptive immunity. Diseases associated with the dysfunction of IFN alpha include Hepatitis C and Hepatitis.
Spezifikation
Spezifikation
| Zugriffsnummer | P01563 |
| Zur Verwendung mit (Anwendung) | Bioactivity |
| Zusammensetzung | PBS with 0.1% BSA and no preservative |
| Gen-ID (Entrez) | 3440 |
| Molekulargewicht | 19.2 kDa |
| Name | Human IFN-alpha A (alpha 2a) |
| Reinigungsverfahren | Purified |
| Menge | 8.4 x 10^6 Einheiten |
| Lagerungsbedingungen | -80°C |
| Kennzeichnung | RUO |
| Mehr anzeigen |
Name des Produkts
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.
Haben Sie Verbesserungsvorschläge?